News

Utilizing Ironshore’s proprietary delayed-release and extended-release technology, DELEXIS, HLD100 is intended for nighttime dosing and is designed to control ADHD symptoms and improve functioning immediately upon awakening and

The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. Under the terms

The trial  was a multicenter, randomized, double-blind, multiple-dose, placebo-controlled study evaluating the efficacy and safety of three dosing regimens of Buprenorphine Sublingual Spray (0.5 mg three times daily

The Company's SFX-01, a synthetic and stabilised version of sulforaphane, is currently in a Phase II trial, SAS (SFX-01 after Subarachnoid Haemorrhage), in the UK. The orphan drug

Novartis claims that the Expand study is the largest study ever undertaken in SPMS. More than 1,600 people with SPMS from 31 countries participated in the study. They

The priority review status shortens the review clock to six months from the usual 10 months. The agency's action date (PDUFA) is 23 February 2017. Clovis Oncology’s application

The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016

In addition to the storage and transportation of drugs used in clinical trials as a service offered by all of Marken’s depots, Marken’s newest Moscow Depot will now

The unique multitenant cloud capabilities of Veeva Vault enable Daiichi Sankyo to easily streamline management of its critical content, providing external partners, such as CROs, the same level